# Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

Source: https://onco.cc/trials/nct06040541/  
OnCo record `nct06040541` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of zoldonrasib (RMC-9805) alone or with daraxonrasib (RMC-6236) in KRAS G12D-mutant solid tumours, including pancreatic, bowel and non-small-cell lung cancer, run by Revolution Medicines, now recruiting.

## Summary

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors is a phase 1/1b interventional study registered as NCT06040541 by Revolution Medicines, Inc., with an estimated 604 participants across the whole study. Two arms are recorded: RMC-9805 (zoldonrasib) monotherapy and RMC-9805 plus RMC-6236 (daraxonrasib). Conditions listed: non-small cell lung cancer, colorectal cancer, pancreatic ductal adenocarcinoma and advanced solid tumours. The registry carries no results; the combination cohort figures reported by the sponsor at ESMO GI 2026 sit on the pairing record g12d-plus-pan-ras.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-21
- Also known as: RMC-9805-001
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06040541
- Phase: 1
- Setting: Phase 1/1b, Multicenter, Open-Label, Study of RMC 9805 in Participants With Advanced KRASG 12D-Mutant Solid Tumors
- Sponsor: Revolution Medicines, Inc.
- Enrolled: 604

## Sources

- ClinicalTrials.gov NCT06040541: https://clinicaltrials.gov/study/NCT06040541

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- targets: [KRAS](https://onco.cc/targets/kras/)
- drugs: [Daraxonrasib](https://onco.cc/drugs/daraxonrasib/), [Zoldonrasib](https://onco.cc/drugs/zoldonrasib/)
- companies: [Revolution Medicines](https://onco.cc/companies/revolution-medicines/)
- pairings: [G12D-selective + pan-RAS(ON) inhibitor (zoldonrasib + daraxonrasib)](https://onco.cc/pairings/g12d-plus-pan-ras/)

---
JSON: https://onco.cc/api/v1/entities/nct06040541.json